Business & FinanceTop StoryTop StoryLatest News
Alembic Pharma Receives USFDA Approval for Generic Ear Infection Drug
Sentiment: NeutralHigh Priority
What Happened?
Alembic Pharmaceuticals has received final approval from the USFDA for its generic Ciprofloxacin and Dexamethasone Otic Suspension, used to treat ear infections in patients aged six months and older.
Key points
- The drug is indicated for treating Acute Otitis Media and Acute Otitis Externa.
- Ciprofloxacin and Dexamethasone Otic Suspension has an estimated market size of USD 110 million.
- Alembic has now received a total of 246 ANDA approvals from the USFDA.
Key insights
- The approval could enhance Alembic's market presence in the US.
- This product's entry may increase competition in the ear infection treatment sector.
- Alembic's growing portfolio of ANDA approvals may attract further investment.
Why it matters
This approval allows Alembic to enter a significant market for ear infection treatments.
Tags
Entities
Alembic Pharmaceuticals· CompanyUSFDA· OrganizationCiprofloxacin· ProductDexamethasone· Product
Source
Business Standard
